Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis

Area of Science:

• Pediatric Neurology
• Epileptology
• Genetics

Background:

• Tuberous sclerosis complex (TSC) is a genetic disorder associated with early-onset seizures.
• Early seizures in TSC are linked to intractable epilepsy and significant cognitive and behavioral deficits.
• Vigabatrin is a common first-line treatment for infantile spasms in TSC.

Purpose of the Study:

• To evaluate the long-term outcomes of infants with TSC-related seizures treated with vigabatrin.
• To determine the impact of early versus delayed vigabatrin treatment on seizure control, intellectual disability, and autism.
• To assess the efficacy of vigabatrin in mitigating the long-term consequences of early seizures in TSC.

Main Methods:

• Retrospective evaluation of 44 infants with TSC presenting with seizures within the first 12 months of life.
• Patients were treated with vigabatrin and followed for a minimum of 3.5 years.
• Outcomes assessed included seizure status, intellectual disability, and autism prevalence, comparing early (<0.01) versus delayed treatment groups.

Main Results:

• 55% of patients remained seizure-positive at final evaluation.
• 80% of patients developed intellectual disability, and 30% had autism.
• Seizure freedom was achieved in 65% of children treated early versus 24% treated later (P<0.01).
• Intellectual disability was present in 61% of early-treated and 100% of late-treated children.
• Autism prevalence was 9% in the early group and 52% in the late group (P≈0.001).

Conclusions:

• Earlier initiation of vigabatrin treatment in infants with TSC is associated with significantly higher rates of seizure freedom.
• Prompt treatment may reduce the incidence and severity of intellectual disability and autism in TSC.
• While early treatment improves outcomes, it does not completely reverse TSC-associated cognitive impairment, highlighting the need for comprehensive management.